Quest Diagnostics Expands Oncology Testing Access Via Flatiron Health's OncoEMR MPI

MT Newswires Live
07/08

Quest Diagnostics (DGX) has expanded access to its oncology testing for solid tumor cancers through Flatiron Health's electronic oncology medical record platform OncoEMR MPI, it said Wednesday.

The integration is expected to allow 4,700 clinicians within the Flatiron network of 1,600 cancer care locations in the US to quickly access Quest's services without leaving their existing workflow, the company said.

Certain providers are now able to order and receive results from Quest using the OncoEMR MPI as part of a pilot program, Quest said, adding that it plans to launch the full OncoEMR MPI integration to providers nationwide in H2.

Shares of Quest Diagnostics were down 0.7%.

Price: 210.12, Change: -1.41, Percent Change: -0.66

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10